Prospective Grant of Exclusive License: Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons, 35637 [2013-14036]

Download as PDF Federal Register / Vol. 78, No. 114 / Thursday, June 13, 2013 / Notices Ron A. Otten, Director, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2013–14037 Filed 6–12–13; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Prospective Grant of Exclusive License: Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). ACTION: Notice. AGENCY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS), is considering granting an exclusive license, in the field of use of vaccine targets for treatment or prevention of diseases in human health and in animal health, to practice the inventions listed in the patent applications referred to below to Codagenix Inc., having a place of business in Stony Brook, New York. The patent rights in these inventions have been assigned to the government of the United States of America. The patent applications(s) to be licensed are: SUMMARY: tkelley on DSK3SPTVN1PROD with NOTICES US Provisional Application 60/617,545, filed 10/8/2004, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; PCT Application PCT/US05/036241, filed 10/ 7/2005, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; US National Stage Application 11/576,941, filed 11/19/2007, entitled ‘‘Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons’’; and all related continuing and foreign patents/patent applications for the technology family. CDC Technology ID No. I–025–04. Status: Pending. Priority Date(s): 10/8/2004. If granted, the licensee will pay CDC royalties in accordance with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. Technology Infections by intracellular pathogens such as viruses, bacteria and parasites, are cleared in most cases after activation of specific T cellular immune responses VerDate Mar<15>2010 16:58 Jun 12, 2013 Jkt 229001 that recognize foreign antigens and eliminate infected cells. Vaccines against those infectious organisms have been traditionally developed by administration of whole live attenuated or inactivated microorganisms. Although research has been performed using subunit vaccines, the levels of cellular immunity induced are usually low and not capable of eliciting complete protection against diseases caused by intracellular microbes. However, CDC inventors discovered that replacement of one or more natural (or native) codons in a pathogen with synonymous non-preferred codons can decrease the replicative fitness of the pathogen, thereby attenuating the pathogen. The non-preferred synonymous codon(s) encode the same amino acid as the native codon(s), but have nonetheless been found to reduce a pathogen’s replicative fitness. This invention teaches compositions and methods that can be used to develop attenuated vaccines having well-defined levels of replicative fitness and enhanced genetic stabilities. Only written comments and/or applications for a license which are received by CDC on or before July 15, 2013 will be considered. 35637 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Environmental Health Sciences; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Environmental Health Sciences Special Emphasis Panel, July 15, 2013, 8:00 a.m. to July 15, 2013, 5:00 p.m., National Institute of Environmental Health Sciences, 111 T.W. Alexander Drive, Research Triangle Park, NC, 27709 which was published in the Federal Register on May 29, 2013, 2013–12635. The meeting notice is amended to change the date of the meeting from July 15, 2013 to July 16, 2013. The meeting is closed to the public. Dated: June 7, 2013. Carolyn Baum, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2013–13997 Filed 6–12–13; 8:45 am] BILLING CODE 4140–01–P DATES: Requests for a copy of these patent applications, inquiries, comments, and other materials relating to the planned license should be directed to Donald Prather, J.D., Ph.D., Technology Licensing and Marketing Specialist, Technology Transfer Office, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop K–79, Atlanta, GA 30341, Telephone: (770) 488–8612; Facsimile: (770) 488–8615; Email: dmprather@cdc.gov. ADDRESSES: SUPPLEMENTARY INFORMATION: Applications for a license filed in response to this notice will be treated as objections to the giving of the planned license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: June 7, 2013. J. Ronald Campbell, Director, Division of Executive Secretariat, Centers for Disease Control and Prevention. [FR Doc. 2013–14036 Filed 6–12–13; 8:45 am] BILLING CODE 4163–18–P PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Functional Assays to Screen Genomic Hits. Date: July 2, 2013. Time: 8:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: YingYing Li-Smerin, MD, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge E:\FR\FM\13JNN1.SGM 13JNN1

Agencies

[Federal Register Volume 78, Number 114 (Thursday, June 13, 2013)]
[Notices]
[Page 35637]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-14036]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Prospective Grant of Exclusive License: Modulation of Poliovirus 
Replicative Fitness by Deoptimization of Synonymous Codons

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice in accordance with 35 U.S.C. 209(e) and 37 
CFR 404.7(a)(1)(i) that the Technology Transfer Office, Centers for 
Disease Control and Prevention (CDC), Department of Health and Human 
Services (HHS), is considering granting an exclusive license, in the 
field of use of vaccine targets for treatment or prevention of diseases 
in human health and in animal health, to practice the inventions listed 
in the patent applications referred to below to Codagenix Inc., having 
a place of business in Stony Brook, New York. The patent rights in 
these inventions have been assigned to the government of the United 
States of America. The patent applications(s) to be licensed are:

    US Provisional Application 60/617,545, filed 10/8/2004, entitled 
``Modulation of Poliovirus Replicative Fitness by Deoptimization of 
Synonymous Codons''; PCT Application PCT/US05/036241, filed 10/7/
2005, entitled ``Modulation of Poliovirus Replicative Fitness by 
Deoptimization of Synonymous Codons''; US National Stage Application 
11/576,941, filed 11/19/2007, entitled ``Modulation of Poliovirus 
Replicative Fitness by Deoptimization of Synonymous Codons''; and 
all related continuing and foreign patents/patent applications for 
the technology family. CDC Technology ID No. I-025-04.

    Status: Pending.
    Priority Date(s): 10/8/2004.
    If granted, the licensee will pay CDC royalties in accordance with 
the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

Technology

    Infections by intracellular pathogens such as viruses, bacteria and 
parasites, are cleared in most cases after activation of specific T 
cellular immune responses that recognize foreign antigens and eliminate 
infected cells. Vaccines against those infectious organisms have been 
traditionally developed by administration of whole live attenuated or 
inactivated microorganisms. Although research has been performed using 
subunit vaccines, the levels of cellular immunity induced are usually 
low and not capable of eliciting complete protection against diseases 
caused by intracellular microbes. However, CDC inventors discovered 
that replacement of one or more natural (or native) codons in a 
pathogen with synonymous non-preferred codons can decrease the 
replicative fitness of the pathogen, thereby attenuating the pathogen. 
The non-preferred synonymous codon(s) encode the same amino acid as the 
native codon(s), but have nonetheless been found to reduce a pathogen's 
replicative fitness. This invention teaches compositions and methods 
that can be used to develop attenuated vaccines having well-defined 
levels of replicative fitness and enhanced genetic stabilities.

DATES: Only written comments and/or applications for a license which 
are received by CDC on or before July 15, 2013 will be considered.

ADDRESSES: Requests for a copy of these patent applications, inquiries, 
comments, and other materials relating to the planned license should be 
directed to Donald Prather, J.D., Ph.D., Technology Licensing and 
Marketing Specialist, Technology Transfer Office, Centers for Disease 
Control and Prevention (CDC), 4770 Buford Highway, Mailstop K-79, 
Atlanta, GA 30341, Telephone: (770) 488-8612; Facsimile: (770) 488-
8615; Email: dmprather@cdc.gov.

SUPPLEMENTARY INFORMATION: Applications for a license filed in response 
to this notice will be treated as objections to the giving of the 
planned license. Comments and objections submitted in response to this 
notice will not be made available for public inspection, and, to the 
extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: June 7, 2013.
J. Ronald Campbell,
Director, Division of Executive Secretariat, Centers for Disease 
Control and Prevention.
[FR Doc. 2013-14036 Filed 6-12-13; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.